Project Details
Key findings
ORM NCE dose dependently (10-80mgkg po, single dose) reverses allodynia in STZ diabetic neuropathy model in line with Pregabalin and ORM positive control.
PKPD determined.
Identified the potential of targeting TRPA1 receptors in type 1 diabetic neuropathic pain.
PKPD determined.
Identified the potential of targeting TRPA1 receptors in type 1 diabetic neuropathic pain.
| Status | Finished |
|---|---|
| Effective start/end date | 31/07/17 → 30/08/17 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.